Gly1057Asp polymorphism of insulin receptor substrate-2 is associated with coronary artery disease in the Taiwanese population

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Chan, Shih Hung ^a,b   Chen, Jyh Hong ^b   Li, Yi Heng ^b   Tsai, Liang Miin ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Coronary artery disease; Diabetes mellitus; Homeostasis model assessment; Insulin receptor substrate; Insulin resistance; Single nucleotide polymorphism

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 2; GLYCINE; INSULIN RECEPTOR SUBSTRATE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT TOOL; CODON; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; ALLELE; ASIAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLYCINE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TAIWAN;

MLCS; MLOWN;

EID: 84870307452     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-100     Document Type: Article

References (37)

1. Genetic susceptibility to death from coronary heart disease in a study of twins. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U, N Engl J Med 1994 330 1041 1046 10.1056/NEJM199404143301503 8127331
2. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham heart study. Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS, Arterioscler Thromb Vasc Biol 2011 31 1208 1214 10.1161/ATVBAHA.110.219055 21311041
3. Banting lecture 1988. Role of insulin resistance in human disease. Reaven GM, Diabetes 1988 37 1595 1607 10.2337/diabetes.37.12.1595 3056758
4. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. DeFronzo RA, Ferrannini E, Diabetes Care 1991 14 173 194 10.2337/diacare.14.3. 173 2044434
5. Diabetes and cardiovascular risk factors: the framingham study. Kannel W, McGee D, Circulation 1979 59 8 13 10.1161/01.CIR.59.1.8 758126
6. The IRS-signalling system: a network of docking proteins that mediate insulin action. White MF, Mol Cell Biochem 1998 182 3 11 10.1023/A:1006806722619 9609109
7. Korenman SG, Kahn CR, Atlas of Clinical Endocrinology, Volume 2, Diabetes United Kindom: Wiley-Blackwell 1999
8. Insulin action, diabetogenes, and the cause of type II diabetes. Kahn CR, Diabetes 1994 43 1066 1084 8039601
9. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. Almind K, Inoue G, Pedersen O, Kahn CR, J Clin Invest 1996 97 2569 2575 10.1172/JCI118705 8647950
10. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Clausen JO, Hansen T, Bjorbaek C, Echwald SM, Urhammer SA, Rasmussen S, Andersen CB, Hansen L, Almind K, Pedersen O, Borch-Johnsen K, Winther K, Haraldsdòttir J, Lancet 1995 346 397 402 10.1016/S0140-6736(95)92779-4 7623569
11. Association of Gly972Arg polymorphism of IRS1 gene with type 2 diabetes mellitus in lean participants of a national health survey in Mexico: a candidate gene study. Burguete-Garcia AI, Cruz-Lopez M, Madrid-Marina V, Lopez-Ridaura R, Hernández-Avila M, Cortina B, Gómez RE, Velasco-Mondragón E, Metab Clin Exp 2010 59 38 45 10.1016/j.metabol.2009.07.007 19716569
12. A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. Baroni MG, D'Andrea MP, Montali A, Pannitteri G, Barilla F, Campagna F, Mazzei E, Lovari S, Seccareccia F, Campa PP, Ricci G, Pozzilli P, Urbinati G, Arca M, Arterioscler Thromb Vasc Biol 1999 19 2975 2980 10.1161/01.ATV.19.12.2975 10591678
13. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Araki E, Lipes MA, Patti M-E, Bruning JC, Haag Iii B, Johnson RS, Kahn CR, Nature 1994 372 186 190 10.1038/372186a0 7526222
14. Disruption of IRS-2 causes type 2 diabetes in mice. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren J-M, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF, Nature 1998 391 900 904 10.1038/36116 9495343
15. Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: evaluation of their relation with alterations in insulin secretion and insulin sensitivity. Almind K, Frederiksen SK, Bernal D, Hansen T, Ambye L, Urhammer S, Ekstrøm CT, Berglund L, Reneland R, Lithell H, White MF, Van Obberghen E, Pedersen O, Diabetologia 1999 42 1244 1249 10.1007/s001250051299 10525667
16. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Mammarella SRF, Di Valerio A, Creati B, Esposito DL, Palmirotta RCF, Vitullo P, Volpe G, Battista P, Della LF, Mariani-Costantini R, Cama A, Hum Mol Genet 2000 9 2517 2521 10.1093/hmg/9.17.2517 11030756
17. Study on the relationship between G1057D variants of IRS2 gene and obese T2DM in Chinese Han subjects. Kong LF, Zhao YY, Li Q, Zheng XM, Ding Q, Liu H, GL L, Chin J Medical Genetics 2005 22 387 390
18. New amino acid substitutions in the IRS-2 gene in Finnish and Chinese subjects with late-onset type 2 diabetes. Wang H, Rissanen J, Miettinen R, Kärkkäinen P, Kekäläinen P, Kuusisto J, Mykkänen L, Karhapää P, Laakso M, Diabetes 2001 50 1949 1951 10.2337/diabetes.50. 8.1949 11473060
19. Expression profiling of macrophages from subjects with atherosclerosis to identify novel susceptibility genes. Hagg DA, Jernas M, Wiklund O, Thelle DS, Fagerberg B, Eriksson P, Hamsten A, Olsson B, Carlsson B, Carlsson LM, Svensson PA, Int J Mol Med 2008 21 697 704 18506362
20. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, JAMA 2003 289 2560 2572 10.1001/jama.289.19.2560 12748199
21. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
22. World Health Organization, Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO consultation Geneva: World Health Organization 2006
23. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R, Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825
24. Use and abuse of HOMA modeling. Wallace TM, Levy JC, Matthews DR, Diabetes Care 2004 27 1487 1495 10.2337/diacare.27.6.1487 15161807
25. The 1975 declaration of helsinki and consent. Shephard DA, Can Med Assoc J 1976 115 1191 1192 1000449
26. G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Li YH, Chen JH, Wu HL, Shi GY, Huang HC, Chao TH, Tsai WC, Tsai LM, Guo HR, Wu WS, Chen ZC, Am J Cardiol 2000 85 8 12 11078228
27. Dawson B, Trapp RG, Basic and clinical biostatistics United States of America: Lange Medical Books/McGraw-Hill 4 2004
28. WHO Regional Office for the Western Pacific, The asia-pacific perspective: redefining obesity and its treatment Manila, Phillippines: World Health Organization 2000
29. Genetic variation in the adiponectin receptor 2 (ADIPOR2) gene is associated with coronary artery disease and increased ADIPOR2 expression in peripheral monocytes. Halvatsiotis I, Tsiotra PC, Ikonomidis I, Kollias A, Mitrou P, Maratou E, Boutati E, Lekakis J, Dimitriadis G, Economopoulos T, Kremastinos DT, Raptis SA, Cardiovasc Diabetol 2010 9 10 10.1186/1475-2840-9-10 20178558
30. Association of ADIPOR2 gene variants with cardiovascular disease and type 2 diabetes risk in individuals with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Siitonen N, Pulkkinen L, Lindstrom J, Kolehmainen M, Schwab U, Eriksson JG, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Cardiovasc Diabetol 2011 10 83 10.1186/1475-2840-10-83 21943112
31. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Chaudhary R, Likidlilid A, Peerapatdit T, Tresukosol D, Srisuma S, Ratanamaneechat S, Sriratanasathavorn C, Cardiovasc Diabetol 2012 11 36 10.1186/1475-2840-11-36 22520940
32. Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. Shah S, Casas JP, Gaunt TR, Cooper J, Drenos F, Zabaneh D, Swerdlow DI, Shah T, Sofat R, Palmen J, Kumari M, Kivimaki M, Ebrahim S, Smith GD, Lawlor DA, Talmud PJ, Whittaker J, Day IN, Hingorani AD, Humphries SE, Eur Heart J 2012 13 13
33. Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. Muendlein A, Saely CH, Geller-Rhomberg S, Sonderegger G, Rein P, Winder T, Beer S, Vonbank A, Drexel H, PLoS One 2011 6 17978 10.1371/journal.pone.0017978 21423583
34. Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Opstad TB, Pettersen AA, Arnesen H, Seljeflot I, Cardiovasc Diabetol 2011 10 110 10.1186/1475-2840-10-110 22141572
35. Prediction of coronary heart disease using risk factor categories. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB, Circulation 1998 97 1837 1847 10.1161/01.CIR.97.18.1837 9603539
36. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular munster (PROCAM) study. Assmann G, Cullen P, Schulte H, Circulation 2002 105 310 315 10.1161/hc0302.102575 11804985
37. New Zealand Guidelines Group, The assessement and management of cardiovascular risk New Zealand: Wellington 2003